Director General of promising biotech companies have to decide how to respond to the macro-economic crisis in late 2008. He planned an aggressive schedule for moving companies and Alzheimer's disease, Parkinson images compounds through clinical trials and to market. This involved the expansion of facilities and staff of the company, and he plans to finance this venture, taking debt. Although clinical trial data is extremely encouraging, the question of raising its next round of enterprise and the overall situation has made him question the wisdom of this plan. This event gives students the opportunity to experience the true value of the company debt and when it is best used to achieve the objectives of all parties -. Venture capitalists, entrepreneurs and enterprises creditors' Hide
by Matthew Rhodes-Kropf, Ann Leamon Source: Harvard Business School 21 pages. Publication Date: 03 February 2009. Prod. #: 809086-PDF-ENG
Related Case Solutions & Analyses:
NAACP
Autozone Inc. (Corporate Finance Strategies)
CHINT Group (B): Moving Up The Value Chain
Clinton Devon Estates: Since 1299; A Culture Of Distinction (A)
Covalys: Managing The Company’s Growth And Development Strategy
Danfoss Motion Controls And Holip (A) (Abridged)
Desso (B): Making It Happen—The Implementation Of A C2C Business Model
Do Star Performers Need To Network? (B): Re-Entry & Visibility: Bénédicte Foucart
Dr. Reddy’s: Medicine Is For People, Profits Follow
National Electric Corp.
